AstraZeneca (AZN) Up on Enhertu, Imfinzi Cancer Data at ESMO (Revised)

Posted byZacks Equity Research Leave a comment on AstraZeneca (AZN) Up on Enhertu, Imfinzi Cancer Data at ESMO (Revised)

AstraZeneca’s (AZN) Enhertu reduces the risk of disease progression by 72% in HER2-positive metastatic breast cancer. Imfinzi plus chemotherapy triple…

Leave a comment

Your email address will not be published. Required fields are marked *